Next-generation radiomic sequencing in non-small cell lung cancer: an alternative model to predict mutations from

Lavinia Monaco1, Cinzia Crivellaro1, Elisabetta De Bernardi2,3

  • 1Nuclear Medicine Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Lombardy, Italy.

Abstract

Insights

[18F]FDG PET/CT radiomics show potential for predicting KRAS mutations in non-small cell lung cancer (NSCLC). A texture complexity feature (FBS_glcm_MCC) was associated with KRAS mutation status, offering a noninvasive imaging biomarker.

Area of Science:

  • Oncology
  • Radiology
  • Medical Imaging
  • Biomarker Discovery

Background:

  • Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality globally.
  • Targeted therapies for EGFR and KRAS mutations improve NSCLC outcomes, but genetic profiling is not always accessible.
  • Radiomics, extracting quantitative features from medical images like [18F]FDG PET/CT, offers a noninvasive approach to assess tumor heterogeneity and identify predictive biomarkers.

Purpose of the Study:

  • To evaluate the potential of [18F]FDG PET/CT radiomic features in predicting mutations in NSCLC.
  • To identify noninvasive imaging biomarkers for EGFR and KRAS mutation status in NSCLC patients.

Main Methods:

  • Retrospective analysis of 105 NSCLC patients with confirmed histology, next-generation sequencing (NGS), and baseline [18F]FDG PET/CT scans.
  • Radiomic features (766 per tumor) were extracted from PET images using Pyradiomics and IBSI-compliant algorithms.
  • Feature selection for mutation association was performed using LASSO logistic regression, with validation on independent datasets from two different PET/CT scanners.

Main Results:

  • No radiomic features were significantly associated with EGFR mutations in the evaluated datasets.
  • A specific radiomic feature, FBS_glcm_MCC (measuring image texture complexity), was significantly associated with KRAS mutation status (AUC=0.68, p=0.04).
  • This texture-based feature demonstrated predictive value for KRAS mutation in an independent validation cohort.

Conclusions:

  • Preliminary findings suggest [18F]FDG PET radiomics may serve as a noninvasive surrogate for genetic profiling in NSCLC, particularly for KRAS mutations.
  • The identified radiomic feature (FBS_glcm_MCC) shows promise as a predictive biomarker.
  • Further validation in larger, diverse patient cohorts is necessary to confirm these findings and clinical utility.